康弘药业
(002773)
| 流通市值：137.89亿 | | | 总市值：185.09亿 |
| 流通股本：6.85亿 | | | 总股本：9.19亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,112,962,184.64 | 4,702,142,704.6 | 2,526,863,956.33 | 2,981,009,984.35 |
| 应收票据及应收账款 | 170,174,404.15 | 160,406,614.48 | 186,223,635.65 | 185,372,955.08 |
| 其中：应收票据 | - | - | 2,722,072.29 | 3,017,579.32 |
| 应收账款 | 170,174,404.15 | 160,406,614.48 | 183,501,563.36 | 182,355,375.76 |
| 预付款项 | 18,681,602.01 | 10,482,586.49 | 32,450,179.75 | 27,388,966.62 |
| 其他应收款合计 | 18,589,941.03 | 7,046,096.18 | 10,234,384.56 | 7,085,886.95 |
| 存货 | 401,554,754.51 | 403,610,615.09 | 377,072,129.86 | 366,066,389.77 |
| 其他流动资产 | 23,413,049.74 | 21,918,464.33 | 15,925,237.33 | 23,789,493.5 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 5,696,165,936.08 | 5,305,607,081.17 | 5,118,739,523.48 | 4,657,683,676.27 |
| 非流动资产: | | | | |
| 长期股权投资 | 16,723,552.85 | 16,776,711.52 | 16,730,797.74 | 16,761,716.53 |
| 固定资产 | 2,204,361,144.36 | 2,237,846,481.5 | 2,253,700,132.94 | 2,231,848,791.63 |
| 在建工程 | 165,151,332.02 | 166,541,809.79 | 171,395,026.31 | 230,481,104.41 |
| 生产性生物资产 | 4,073,658.37 | 4,554,372.73 | 4,860,418.69 | 5,590,855.34 |
| 使用权资产 | 1,988,979.68 | 2,123,238.61 | 3,375,438.67 | 3,857,574.64 |
| 无形资产 | 309,151,412.03 | 316,803,925.3 | 320,608,818.72 | 322,525,714.86 |
| 开发支出 | 93,517,224.52 | 92,144,094.97 | 82,787,538.35 | 74,500,018.52 |
| 长期待摊费用 | 6,184,683.99 | 7,190,882.55 | 6,381,202.89 | 7,376,793.78 |
| 递延所得税资产 | 312,276,800.22 | 358,078,120.48 | 386,185,065.28 | 430,478,503.66 |
| 其他非流动资产 | 23,753,633.97 | 22,014,192.08 | 27,568,857.77 | 36,091,523.05 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,137,182,422.01 | 3,224,073,829.53 | 3,273,593,297.36 | 3,359,512,596.42 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 8,833,348,358.09 | 8,529,680,910.7 | 8,392,332,820.84 | 8,017,196,272.69 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 255,973,214.44 | 344,029,888.6 | 301,448,889.72 | 340,281,750.11 |
| 应付账款 | 255,973,214.44 | 344,029,888.6 | 301,448,889.72 | 340,281,750.11 |
| 预收款项 | 16,268,754.88 | 3,882,684.2 | 4,003,438.96 | 2,654,739 |
| 合同负债 | 6,667,982.25 | 5,100,351.22 | 6,835,722.93 | 6,234,862.89 |
| 应付职工薪酬 | 38,683,913.34 | 133,984,230.83 | 22,926,977.92 | 40,125,646.71 |
| 应交税费 | 55,220,871.26 | 35,954,316.01 | 55,472,500.72 | 47,029,932.53 |
| 其他应付款合计 | 181,442,349.19 | 64,358,028.63 | 268,344,909.64 | 147,440,674.44 |
| 一年内到期的非流动负债 | 407,555.43 | 531,817.42 | 1,305,920.98 | 1,684,127.89 |
| 其他流动负债 | 39,830,765.79 | 66,590,505.46 | 56,626,352.51 | 49,262,833.62 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 594,495,406.58 | 654,431,822.37 | 716,964,713.38 | 634,714,567.19 |
| 非流动负债: | | | | |
| 租赁负债 | 1,517,414.03 | 1,479,498.27 | 1,653,585.51 | 1,802,021.85 |
| 长期应付款 | 26,849,036.55 | 36,599,821.39 | 49,228,466.91 | 61,372,753.83 |
| 递延收益 | 18,536,660.08 | 17,307,968.97 | 22,024,277.86 | 22,440,586.75 |
| 递延所得税负债 | 8,578,813.88 | 7,944,751.41 | 6,880,185.21 | 6,283,995.61 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 55,481,924.54 | 63,332,040.04 | 79,786,515.49 | 91,899,358.04 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 649,977,331.12 | 717,763,862.41 | 796,751,228.87 | 726,613,925.23 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 919,463,954 | 919,463,954 | 919,463,954 | 919,463,954 |
| 资本公积 | 1,990,162,751.84 | 1,989,597,189.13 | 1,988,077,232.35 | 1,995,893,152.26 |
| 其他综合收益 | -1,928,124.9 | -1,341,442.82 | -1,255,244.28 | -1,097,544.44 |
| 盈余公积 | 515,315,206.97 | 515,315,206.97 | 489,678,558.8 | 487,160,738.96 |
| 未分配利润 | 4,754,515,972.41 | 4,380,994,499.35 | 4,187,226,754.98 | 3,889,722,397.62 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 8,177,529,760.32 | 7,804,029,406.63 | 7,583,191,255.85 | 7,291,142,698.4 |
| 少数股东权益 | 5,841,266.65 | 7,887,641.66 | 12,390,336.12 | -560,350.94 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 8,183,371,026.97 | 7,811,917,048.29 | 7,595,581,591.97 | 7,290,582,347.46 |
| 负债和股东权益合计 | 8,833,348,358.09 | 8,529,680,910.7 | 8,392,332,820.84 | 8,017,196,272.69 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-27 | 2023-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |